# **CAPTISOL® AS CHIRAL SELECTOR IN CAPILLARY ELECTROPHORESIS OF NON-ACIDIC DRUGS**

MONICA BUDĂU<sup>1</sup>, GABRIEL HANCU<sup>1\*</sup>, ZOLTÁN ISTVÁN SZABÓ<sup>2</sup>, HAJNAL KELEMEN<sup>1</sup>, AURA RUSU<sup>1</sup>, DANIELA LUCIA MUNTEAN<sup>3</sup>, ANCA GABRIELA CÂRJE<sup>3</sup>

<sup>1</sup>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy, Târgu Mureş, Romania; <sup>2</sup>Department of Pharmaceutical Industry and Pharmaceutical Management, Faculty of Pharmacy, University of Medicine and Pharmacy, Târgu Mureş, Romania;

<sup>3</sup> Department of Analytical Chemistry and Drug Analysis, Faculty of Pharmacy, University of Medicine and Pharmacy, Târgu Mureş, Romania;

# ABSTRACT

Enantioseparation of nine extensively used chiral pharmaceutical substances from different pharmacological classes and with different structural characteristics has been investigated by capillary zone electrophoresis using Captisol® (sulfobuthylether- $\beta$ -cyclodextrin sodium salt) as chiral selector. The influence on the chiral separation of several parameters including pH and concentration of the background electrolyte, chiral selector concentration, applied voltage, system temperature and injection parameters were studied and optimized in order to obtain increased chiral resolution and shorten analysis time. The results were compared with those obtained with native and derivatized neutral cyclodextrins ( $\beta$ -cyclodextrin and hydroxypropryl- $\beta$ -cyclodextrin). All model molecules were resolved using Captisol® as chiral additive and optimized electrophoretic conditions, proving the efficiency of this anionic derivative of  $\beta$ - cyclodextrin as chiral selector in capillary electrophoresis.

Keywords: chiral separation, Captisol®, capillary electrophoresis, cyclodextrines, pharmaceutical analysis

# **INTRODUCTION**

Almost half of the drugs currently used in therapy have a chiral center in the molecule, but only approximately 25% of them are administered in the form of a pure enantiomer. It is well known that usually the aimed pharmacological effect is restricted to one of the enantiomers, called eutomer; while the other enantiomer, called distomer can be inactice, less active or sometimes can cause unwanted adverse effects. Enantiomers differ in terms of absorption, distribution, metabolic pathway or binding affinity to proteins and receptors.<sup>1</sup>

Chiral drugs are generally synthesized as racemic mixtures or as single enantiomers; analysis of a pharmaceutical form comprising of a single enantiomer requiring sometimes determination of very low concentrations of enantiomer impurity levels of less than 1%. Quantification of these concentration levels is often difficult and challenging for the analyst, especially when good selectivity and high sensitivity is required. The most frequently used separation technique in the enantioseparation of pharmaceutical substances is without doubt high performance liquid chromatography (HPLC), but in recent years capillary electrophoresis (CE) is gaining more and more followers in modern chiral analysis.<sup>2</sup>

The advantages of CE compared to conventional HPLC methods in the enantioseparation of chiral substances are being related to the: rapid and simple method development, small amounts of solvent, sample and chiral selector required for the separation and especially with the high selectivity in choosing and changing the chiral selector. Also in CE, usually a direct method of separation is used, by simply adding the chiral selector in the background electrolyte (BGE).<sup>23,4</sup>

In order to obtain chiral separation, the enantiomers have to come into contact with a chiral environment and to form two different diastereomeric complexes. According to the rule of three points of interaction by Dlagliesh, chiral recognition depends on at least three simultaneous interactions between selector and chiral molecule and at least one of these interactions needs to be stereoselective in order to allow enantiomer discrimination.<sup>2</sup>

Cyclodextrines (CDs) are by far the most frequently used chiral additives in CE; in modern chiral analysis a large number of native and derivatized, neutral and ionized CD derivatives being used as chiral selectors. CDs mechanism as chiral selector involves a complexation through inclusion of the hydrophobic part of the analyte in the hydrophobic cavity of the CD. The stability of the formed complex is influenced by several parameters, including chemical structure and hydrophobicity of the analyte, CD type and concentration, background electrolyte (BGE) composition, buffer pH and temperature.<sup>5,6</sup>

The utility of native CDs as chiral additives is sometimes limited, and therefore a large number of derivatized CDs have been developed and introduced as chiral selectors. By derivatization, hydrophobicity and charge can be altered and affect, electrophoretic mobility or complexing ability of the analytes. Enantioseparation by CE requires that either the analyte or the used CD is electrically charged.<sup>46,7</sup>

The use of charged CDs enables additional electrostatic interactions between analyte and the chiral selector, which can significantly influence the resolution of the enantiomers. Charged CDs can be employed for the chiral separation of both charged and uncharged analytes, because, in the ionized state, this type of CDs migrates with their own electrophoretic mobility. Further advantages of charged CD derivatives are related to the better solubility and the ability to display additional electrostatic interactions.<sup>5,7,8</sup>

Captisol<sup>®</sup> is a particular type of sulfobutyl ether derivative of  $\beta$ -CD with a range of six to seven sulfobutyl ether groups per CD molecule (**figure 1**). Because of the very low pKa of the sulfonic acid groups, Captisol<sup>®</sup> carries multiple negative charges at physiologically compatible pH values. The fourcarbon butyl chain coupled with repulsion of the end group negative charges allows for an "extension" of the CD cavity. This often results in stronger binding to drug candidates than can not be achieved using other modified CDs. It also provides a potential for ionic charge interactions between the CD and a positively charged drug molecule. Captisol<sup>®</sup> was rationally designed in order to maximize safety and optimize interaction to improve the solubility, stability and administration of active ingredients.<sup>9,10,11</sup>



Sulfobutyl Ether-β-Cyclodextrin (Captisol®)

Figure 1: Captisol<sup>®</sup> (sulfobutyl ether  $\beta$ -cyclodextrin sodium salt) chemical structure.

Sulfobuthylether- $\beta$ -cyclodextrins (SBE- $\beta$ -CDs) are anionic derivatives of  $\beta$ -CD that has proven during the years to be successful in separating a large variety of enantiomeric compounds. Usually SBE- $\beta$ -CDs used as chiral selectors have an average degree of substitution of four and a substitution range from one to ten. Previous works with SBE- $\beta$ -CD has shown that several compounds exhibited peak tailing and loss of efficiency due to the electrodispersion phenomenon.<sup>12,13,14,15</sup>

The first application of SBE- $\beta$ -CD as chiral selector in CE was described 20 years ago for the separation of ephedrine, pseudoephedrine and several structurally related compounds <sup>12</sup>; and since then different types of SBE- $\beta$ -CD with specific degrees of substitution have been used for the chiral discrimination of basic drugs <sup>14,15</sup>; as a recent example Captisol® was applied successfully for the separation of 16 benzofurys and other psychoactive compounds used on the illicit market as recreational drugs in an aqueous ammonium acetate solution containing actonitrile.<sup>16</sup>

In the present investigation, a number of nine optically active pharmaceutical substances were selected as model compounds to assess the utility of Captisol® as chiral selector. These compounds represent excellent examples of the need for chiral specific determination procedures because of the stereoselectivity of their pharmacological activities. Different compounds from different therapeutic classes were selected due to their great prevalence in therapy and also taking in consideration their particular structural and stereochemical characteristics. As model molecules we selected  $\beta$ -adrenergic receptor blockers (carvedilol, propranolol, sotalol), H1 antihistamines (cetirizine, promethazine), dihydropyridine calcium channel blocker (amlodipine), selective serotonin reuptake inhibitor (fluoxetine), diuretic (indapamide), opioid analgesic (tramadol).

# **EXPERIMENTAL**

#### Apparatus

Analyses were performed using an Agilent 7100 CE system (Agilent, Waldbronn, Germany) equipped with a diode-array-detector (DAD). For the separation we used silica-fused capillaries (Agilent, Waldbronn, Germany) with a total length of 48.5 cm (effective length of 40 cm) and an internal diameter of 50 µm. The data was processed using Chemstation 7.01 (Agilent, Germany) software. The pH of the buffer solutions was measured with a Terminal 740 pH–meter (Inolab, Germany). The UV spectrum of the studied substances was recorded with a Specord 210 spectrophotometer (Analytik Jena, Germany).

Chemicals and reagents

The racemic mixtures of the selected chiral compounds were obtained from various sources: R,S-amlodipine besiltate (Fako Ilaclari A.S, Istanbul, Turkey), R,S-carvedilol (Sun Pharmaceutical Industries, Mumbai, India), R,Scetirizine hydrochloride (Tonira Pharma Ltd., Guajarat, India), R.S-fluoxtine hydrochloride (Mantena Laboratories Ltd, Hyderabad, India), R,S-indapamide (Moehs Productos Quimicos, Barcelona, Spain), R,S-promethazine hydrochloride (Morepen Laboratories Ltd., New Delhi, India), R,S-propranolol hydrochloride (Moehs Productos Quimicos, Barcelona, Spain), R,S-sotalol hydrochloride (Moehs Productos Quimicos, Barcelona, Spain), R,S-tramadol hydrochloride (Sun Pharmaceutical Industries, Mumbai, India). For four of the studied chiral substances we had at our disposal also pure enantiomers: S-carvedilol (Sun Pharmaceutical Industries, Mumbai, India), R-cetirizine hydrochloride (Tonira Pharma Ltd., Guajarat, India), R-propranolol (Moehs Productos Quimicos, Barcelona, Spain), S-sotalol hydrochloride (Moehs Productos Quimicos, Barcelona, Spain). All of the studied substances were of pharmaceutical grade.

Captisol® (SBE- $\beta$ -CD sodium salt, research grade, average degree of substitution: 6.5) was obtained from Cydex Pharmaceuticals Inc. (La Jolla, CA, USA). The neutral CDs ( $\beta$ -CD and HP- $\beta$ -CD) were obtained from Cyclolab (Budapest, Hungary).

The following reagents of analytical grade were used: phosphoric acid (Chimopar, Bucharest, Romania), methanol, sodium hydroxide (Lach Ner, Neratovice, Czech Republic), sodium tetraborate, disodium hydrogenophosphate, sodium didydrogenophosphate (Merck, Darmstadt Germany). Purified water was prepared using a Milli-Q Plus water purification system (Millipore, Milford, MA, USA).

# Sample peparation

Sample stock solutions were prepared by dissolving the substances in methanol in a concentration of 100  $\mu$ g/mL and later diluted to the appropriate concentration. The samples were introduced in the system at the anodic end of the capillary by hydrodynamic injection. All samples and buffers were filtered through a 0.45  $\mu$ m pore size Cellulose filter and degassed for 5 minutes using an ultrasonic bath.

#### Electrophoretic procedure

Every time before starting the experiments, the capillary was conditioned by flushing 10 minutes with water, 15 minutes with 0.1 M NaOH and 5 minutes with buffer electrolyte. The capillary was rinsed for 1 minute with 0.1M sodium hydroxide and buffer solutions before each electrophoretic determination.

In the preliminary analysis we applied some "standard" electrophoretic conditions for a CE analysis: temperature 20°C, applied voltage + 25 kV, injection pressure/time 50 mbar/3 sec, sample concentration 10  $\mu$ g/ml.

UV-spectra of the analytes were recorded in a range of 200 and 400 nm in order to determine the optimum detection wavelength of each compound.

### **RESULTS AND DISCUSSION**

The chemical structures of the selected substances are presented in **figure** 2.

Taking in consideration the pKa values and the structural characteristics of the selected substances we can conclude that the large majority of the selected substances exhibit basic characteristics, excepting cetirizine which is a zwitterionic molecule.

To find the suitable conditions for the chiral separation of the model molecules, a series of preliminary experiments were conducted with different buffer compositions at different pH values, in order to characterize the electrophoretic behavior of the analytes in an achiral system over a wide adjustable pH range (2-11). In the preliminary analysis we used: 25 mM phosphoric acid (pH –2.1), 25 mM sodium didydrogenophosphate (pH – 5.0), 25 mM disodium hydrogenophosphate – sodium didydrogenophosphate (1:1) (pH – 7.0) and 25 mM sodium tetraborate (pH – 9.3) BGEs respectively and we modified the pH of the buffer by adding a 0.1M sodium hydroxide solution.

Afterwards, the CDs were added in the buffer solutions, and the electrophoretic behavior of the analytes in a chiral system was observed and characterized over the same pH range. In the screening process initial concentration of 10 mM for the neutral CDs and 5 mM for SBE- $\beta$ -CD were used.

Buffer pH is an important condition in CE, as the degree of dissociation of the charged selector, analyte charge, and the electroosmotic flow (EOF) are all affected by pH.<sup>19,20</sup> When pH increased, the velocity of the EOF increased and migration times were shorter; as it is well known that EOF will increase considerably with increasing pH.

While  $\beta$ -CD and HP- $\beta$ -CD are not charged, an advantage of using SBE- $\beta$ -CD as chiral selector is that it maintains its charge over the entire pH range useful in CE, as the presence of the sulfonic group makes the CD derivative negatively charged over the studied pH range.<sup>13,14</sup> Using an acidic BGE, Captisol® migrates towards the anode and the enantiomers of the basic drugs migrates towards the cathode, while EOF is close to zero; resulting in very long migration times for the studied analytes and weak chiral interactions.

At acidic pH values the weak EOF cannot compensate for the negative electrophoretic mobility of the anionic charged CD, which interacts strongly with the basic compounds, delaying their migration towards the cathode.

Captisol® proved to be an efficient chiral selector when using BGE with pH values above 5.0; as at pH values above 5.0 are favored ion pairing interaction between the positively charged analytes and the anionic CD, thus, transporting the analyte towards the anode.

An increase in the buffer concentration, increases ionic strength and decreases EOF, affecting electrostatic interactions between Captisol® and analytes, resulting in increased analysis time and improved peak shapes. However the increase of the buffer concentration is limited by band broadening due to Joule effect caused by increased current; consequently in the current study we used buffer concentrations of 25 mM.

Compared with neutral CDs the effect of the concentration of charged CDs on the selectivity of the enantioseparation is more pronounced. <sup>19,20</sup> We investigated experimentally the optimum concentration of Captisol® from 1 to 10 mM; as higher concentration generated high currents which led to the instability of the electrophoretic system. For the neutral CD we investigated the effect of CD concentration on an interval between 5 and 25 mM. An increase of Captisol® concentration increased also analysis time of the analytes, probably because changes in the viscosity of the buffer, and changes in EOF due to increase of the migration time of the analytes (with detection at the cathode) because they are transported to the anode due to complexation by the negatively charged CE. The optimum Captisol® concentration was set at 5 mM.

Addition of an organic modifier such as methanol or acetonitrile to the buffer resulted only in longer migration times as there was no significant improvement in the chiral separation.

Running voltage did not have a strong effect on the resolution; while a decrease in temperature led to extension in analysis time and to an increase of the chiral resolution. An equilibrium between applied voltage and system temperature should be established, in order to obtain an adequate resolution of the separation and a satisfactory analysis time. Taking in consideration these

aspects we used a voltage of + 25 kV at a temperature of 15  $^{\circ}$ C.

The injection parameters (injection pressure and time) had an important effect on the peaks shape and amplitude; in order to achieve a quantifiable signal/noise ratio and to avoid band broadening we chose a high injection pressure (50 mbar) and a short injection time (1 second).



Figure 2: Chemical structures of the selected compounds. The chiral centers are marked with an asterix.<sup>17,18</sup>

**Table 1** summarizes the optimum experimental conditions (CD type and concentration, buffer pH) and the results (migration times of the separated zones  $-t_1$  and  $t_2$ , separation factor —  $\alpha$ , resolution — R) obtained for those compounds, which had stereoselective interactions.

Chiral compound	Chiral selector	CD concentration [mM]	рН	t <sub>1</sub> (min)	t <sub>2</sub> (min)	R	α
Amlodipine	β-CD	15	2.50	6.30	`6.45	0.86	1.02
	HP-β-CD	20	2.50	4.50	4.90	2.17	1.08
	SBE-β-CD	5	7.00	11.40	12.30	2.79	1.08
Carvedilol	β-CD	10	2.50	11.00	11.50	2.74	1.04
	HP-β-CD	20	2.50	12.90	13.50	2.54	1.04
	SBE-β-CD	5	9.30	5.80	6.20	1.93	1.05
Cetirizine	β-CD	-	-	-	-	-	-
	HP-β-CD	-	-	-	-	-	-
	SBE-β-CD	5	7.00	6.40	7.00	2.54	1.08
Fluoxetine	β-CD	-	-	-	-	-	-
	HP-β-CD	-	-	-	-	-	-
	SBE-β-CD	5	9,30	6.20	6.30	0.85	1.01
Indapamide	β-CD	-	-	-	-	-	-
	HP-β-CD	-	-	-	-	-	-
	SBE-β-CD	5	7.00	5.70	6.30	4.30	1.10
Promethazine	β-CD	10	2.50	10.50	10.70	0.88	1.02
	HP-β-CD	-	-	-	-	-	-
	SBE-β-CD	5	7.00	9.70	10.10	1.55	1.04
Propranolol	β-CD	10	2.50	9.40	9.80	1.13	1.04
	HP-β-CD	10	2.50	11.00	11.50	1.46	1.04
	SBE-β-CD	5	9.30	4.80	5.00	1.23	1.04
Sotalol	β-CD	-	-	-	-	-	-
	HP-β-CD	20	2.50	9.30	9.70	0.93	1.03
	SBE-β-CD	5	9.30	4.20	4.45	1.53	1.05
Tramadol	β-CD	-	-	-	-	-	-
	HP-β-CD	-	-	-	-	-	-
	SBE-β-CD	5	9.30	3.95	4.20	1.52	1.06

Table 1: Capillary electrophoretic chiral separation data of model compounds

The separation factors ( $\alpha$ ) were calculated as the ratio of the migration times of the optical isomers, and the resolution (R) was obtained by the R=2(t<sub>2</sub> - t<sub>1</sub>)/(w<sub>1</sub> + w<sub>2</sub>) equation, where the migration times (t<sub>1</sub> and t<sub>2</sub>) and the peak-widths (w<sub>1</sub> and w<sub>2</sub>) were marked for the slow and fast migrating enantiomers, respectively. The separation factors and resolution parameters are characterizing the separation. A value above 1.04 for  $\alpha$  and above 1.50 for R generally means baseline separation of the two enantiomers.

From the nine tested molecules, stereoselective interactions when using Captisol® as chiral selector were observed for all compounds, eight being baseline separated and for one (fluoxetine) we noticed only a slight peak splitting. In contrast no chiral resolution was obtained when using the two neutral CDs for four of the model compounds (cetirizine, fluoxetine, indapamide, tramadol), and for promethazine and sotalol only peak splitting was observed.

When using Captisol® at neutral and basic pH values of the BGE we

obtained sistematically better chiral resolution and shorter migration times for the analytes in comparison with the results obtained with  $\beta$ -CD and HP- $\beta$ -CD respectively.

The electropherograms of the enantioseparations of the studied substances when using Captisol $\mathbb{R}$  as chiral selector are presented in **figure 3**.

Tramadol have two chiral centers, but actually is a mixture of only 2 of the theoretically possible stereoisomer, i.e. the (1R,2R) and (1S,2S) stereoisomers, which migrated always in two zones with approximately equal peak areas.

The migration order of the studied enantiomers was verified by analyzing the racemic mixtures with the pure enantiomers. We established the migration order for four of the studied substances using the optimized electrophoretic conditions presented before (table 2). Dependent on the interaction between CD and analyte, the enantiomer with the stronger affinity to the selector migrates slower.



**Figure 3:** Chiral separation of the model compounds using Captisol® as chiral selector (conditions: buffer concentration: 25 mM, Captisolconcentration: 5 mM, applied voltage: + 25 kV, temperature: 15 °C, injection pressure/time: 50 mbar/1 sec.)

 Table 2 Migration order of enantiomers when using optimized separation conditions and Captisol® as chiral selector.

Chiral compoundEnantiomer 1Enantiomer 2CarvedilolR(+)-carvedilolS(-)-carvedilolCetirizineR(-)-cetirizineS(+)-cetirizinePropranololS(-)-propranololR(+)-propranololSotalolR(-)-sotalolS(+)-sotalol

# CONCLUSIONS

Captisol® increase the mobility differences between effective mobility of the complexes formed between the enantiomers and the CD, showed potential for electrostatic interactions that may help to stabilize complexes with analytes bearing opposite charges, which resulted in a wider separation window and potentially greater resolving power for the basic drugs. The sulfonic groups provide a CD derivative, which is anionic over the entire pH range accessible to CE experiments and which can thereby lead to ionic interaction in addition to the hydrophobic inclusion.

The optimal separation conditions for the the analytes were different in several cases; as there are three main aspects that should be considered in understanding and explaining the chiral separation process: the role of the chemical structure of the analyte, the effect of the experimental parameters and the structure of the chiral selector. The changes in the concentration of the chiral selector and in the pH of the BGE showed uneven effect on the resolution of the optical isomers. No direct correlation due to increase or decrease of the respective concentration or pH was noticed.

Captisol® can be successfully applied to the chiral separation of a large variety of optically active substances (amlodipine, carvedilol, cetirizine, indapamide, promethazine, propranolol, sotalol, tramadol), showing strong resolving power especially towards neutral and basic drugs while its selectivity for negatively charged analytes is poor. The presented methods may be used in routine control methods to assess the optical purity of different pharmaceutical substances with a relatively high chiral resolution and short analysis time.

# ACKNOWLEDGMENT

Our work was supported with a project funded through Internal Research Grants by the University of Medicine and Pharmacy of Tîrgu Mureş, Romania (grant contract for execution of research projects nr. 22).

# REFERENCES

- 1. L.A. Nguyen, H. He, C. Pham-Huy, Int. J. Biomed. Sci. 2, 85, (2006).
- 2. G. Gübitz, M.G. Schmid (eds.), Chiral Separations Methods and Protocols. Humana Press, Totowa, New Jersey, 2004.
- 3. P. Schmitt-Kopplin (eds.), Capillary electrophoresis Methods and Protocols. Humana Press, Totowa, New Jersey, 2008.
- P. Mikus, Chiral Capillary Electrophoresis in current Pharmaceutical and Biomedical Analysis, InTech, Rijeka, 2012.
- 5. T. Schnitt, H. Engelhardt, Chromatographia 37, 475, (1993).
- 6. G. Gübitz, M.G. Schmid, J. Chromatogr. A 792, 179, (1997).
- 7. G. Gübitz, M.G. Schmid, J. Chromatogr. A 1204, 140, (2008).
- 8. L. Suntornsuk, Anal. Bioanal. Chem. 398, 29, (2010).
- 9. S. Sotthivirat, J.L. Haslam, V.J. Stella, Int. J. Pharm. 330, 73, (2007).
- D.R. Luke, K. Tomaszewki, B. Damle, H.T. Schlamm, J. Pharm. Sci. 99, 3291, (2010).
- 11. A. Espada, M. Molina-Martin, Drug Discov. Today 17, 396, (2012).
- R.J. Tait, D.O. Thompson, V.J. Stella, J.F. Stobaugh, Anal. Chem. 66, 4013, (1994).
- 13. C. Desidorio, S. Fanali, J. Chromatogr. A 716, 183, (1995).
- D.J. Skanchy, G.H. Xie, R.J. Tait, E. Luna, C. Demarest, J.F. Stobaugh, Electrophoresis 20, 2638, (1999).
- X. Ren, Y Dong, J. Liu, A. Huang, H. Liu, Y. Sun, Z. Sun, Chromatographia 50, 363, (1999).
- M. Taschwer, M.G. Hofer, M.G. Schmid, Electrophoresis 35, 2793, (2014).
- J:H. Block, J.M Beale (eds.), Wilson and Gisvold's textbook of Organic Medicinal and Pharmaceutical Chemistry. 12<sup>th</sup> edition, Lippincott Williams&Wilkins, Philadelphia, 2011.

- Martindale, The Complete Drug Reference, 37<sup>th</sup> edition, Pharmaceutical Press, London, 2011.
- 19. M. Dolezalova, S. Fanali, Electrophoresis 21, 3264, (2000).
- G.S. Yang, D.M. Chen, Y. Yang, B. Tang, J.J. Gao, H.Y. Aboul-Enein, B. Koppenhoefer, Chromatographia 62, 441, (2005).